Literature DB >> 16473273

Reconstructing a disease: What essential features of the retinoic acid receptor fusion oncoproteins generate acute promyelocytic leukemia?

Jonathan D Licht1.   

Abstract

Acute promyelocytic leukemia (APL) is associated with rearrangement of the retinoic acid receptor alpha (RARalpha) gene leading to the formation of chimeric receptor proteins. In this issue of Cancer Cell, studies by Kwok et al. and Sternsdorf et al. indicate that the ability of the RARalpha oncoproteins to dimerize/multimerize is an essential feature required for the development of disease. Homodimerization allows RARalpha to bind to corepressors with increased affinity and the ability to bind to novel DNA sequences. However, artificial RARalpha dimers were weak oncogenes in vivo, indicating that the fusion partners confer additional properties to RARalpha to efficiently generate disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16473273     DOI: 10.1016/j.ccr.2006.01.024

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  21 in total

1.  Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.

Authors:  Rihab Nasr; Hugues de Thé
Journal:  Int J Hematol       Date:  2010-05-11       Impact factor: 2.490

2.  Dimerization-induced corepressor binding and relaxed DNA-binding specificity are critical for PML/RARA-induced immortalization.

Authors:  Jun Zhou; Laurent Pérès; Nicole Honoré; Rihab Nasr; Jun Zhu; Hugues de Thé
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205

3.  Aberrant chromatin remodeling by retinoic acid receptor alpha fusion proteins assessed at the single-cell level.

Authors:  Jihui Qiu; Ying Huang; Guoqiang Chen; Zhu Chen; David J Tweardy; Shuo Dong
Journal:  Mol Biol Cell       Date:  2007-08-01       Impact factor: 4.138

4.  PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.

Authors:  Daniela Bräuer-Hartmann; Jens-Uwe Hartmann; Alexander Arthur Wurm; Dennis Gerloff; Christiane Katzerke; Maria Vittoria Verga Falzacappa; Pier Giuseppe Pelicci; Carsten Müller-Tidow; Daniel G Tenen; Dietger Niederwieser; Gerhard Behre
Journal:  Cancer Res       Date:  2015-06-03       Impact factor: 12.701

Review 5.  Leukaemogenesis: more than mutant genes.

Authors:  Jianjun Chen; Olatoyosi Odenike; Janet D Rowley
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

6.  PML-RARα enhances constitutive autophagic activity through inhibiting the Akt/mTOR pathway.

Authors:  Ying Huang; Jia-Kai Hou; Ting-Ting Chen; Xu-Yun Zhao; Zhao-Wen Yan; Jing Zhang; Jie Yang; Scott C Kogan; Guo-Qiang Chen
Journal:  Autophagy       Date:  2011-10-01       Impact factor: 16.016

7.  FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias.

Authors:  Cécile Esnault; Ramy Rahmé; Kim L Rice; Caroline Berthier; Coline Gaillard; Samuel Quentin; Anne-Lise Maubert; Scott Kogan; Hugues de Thé
Journal:  Blood       Date:  2019-01-23       Impact factor: 22.113

8.  Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.

Authors:  Julien Ablain; Kim Rice; Hassane Soilihi; Aurélien de Reynies; Saverio Minucci; Hugues de Thé
Journal:  Nat Med       Date:  2014-01-12       Impact factor: 53.440

9.  Disruption of the PHRF1 Tumor Suppressor Network by PML-RARα Drives Acute Promyelocytic Leukemia Pathogenesis.

Authors:  Céline Prunier; Ming-Zhu Zhang; Santosh Kumar; Laurence Levy; Olivier Ferrigno; Guri Tzivion; Azeddine Atfi
Journal:  Cell Rep       Date:  2015-02-12       Impact factor: 9.423

10.  Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist.

Authors:  Michael R McKeown; M Ryan Corces; Matthew L Eaton; Chris Fiore; Emily Lee; Jeremy T Lopez; Mei Wei Chen; Darren Smith; Steven M Chan; Julie L Koenig; Kathryn Austgen; Matthew G Guenther; David A Orlando; Jakob Lovén; Christian C Fritz; Ravindra Majeti
Journal:  Cancer Discov       Date:  2017-07-20       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.